BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 23826219)

  • 1. Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer.
    Ligthart ST; Coumans FA; Bidard FC; Simkens LH; Punt CJ; de Groot MR; Attard G; de Bono JS; Pierga JY; Terstappen LW
    PLoS One; 2013; 8(6):e67148. PubMed ID: 23826219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unbiased and automated identification of a circulating tumour cell definition that associates with overall survival.
    Ligthart ST; Coumans FA; Attard G; Cassidy AM; de Bono JS; Terstappen LW
    PLoS One; 2011; 6(11):e27419. PubMed ID: 22087312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer.
    Deutsch TM; Riethdorf S; Nees J; Hartkopf AD; Schönfisch B; Domschke C; Sprick MR; Schütz F; Brucker SY; Stefanovic S; Sohn C; Pantel K; Trumpp A; Schneeweiss A; Wallwiener M
    Breast Cancer Res Treat; 2016 Nov; 160(2):277-290. PubMed ID: 27696083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
    Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
    BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer.
    Meyer CP; Pantel K; Tennstedt P; Stroelin P; Schlomm T; Heinzer H; Riethdorf S; Steuber T
    Urol Oncol; 2016 May; 34(5):235.e11-6. PubMed ID: 26795608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.
    Goodman OB; Symanowski JT; Loudyi A; Fink LM; Ward DC; Vogelzang NJ
    Clin Genitourin Cancer; 2011 Sep; 9(1):31-8. PubMed ID: 21705286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating tumor cells in solid tumor in metastatic and localized stages.
    Maestro LM; Sastre J; Rafael SB; Veganzones SB; Vidaurreta M; Martín M; Olivier C; DE La Orden VB; Garcia-Saenz JA; Alfonso R; Arroyo M; Diaz-Rubio E
    Anticancer Res; 2009 Nov; 29(11):4839-43. PubMed ID: 20032444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating tumor cells count predicts survival in colorectal cancer patients.
    Romiti A; Raffa S; Di Rocco R; Roberto M; Milano A; Zullo A; Leone L; Ranieri D; Mazzetta F; Medda E; Sarcina I; Barucca V; D'Antonio C; Durante V; Ferri M; Torrisi MR; Marchetti P
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):279-84. PubMed ID: 25267956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
    Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
    Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.
    Sastre J; Maestro ML; Gómez-España A; Rivera F; Valladares M; Massuti B; Benavides M; Gallén M; Marcuello E; Abad A; Arrivi A; Fernández-Martos C; González E; Tabernero JM; Vidaurreta M; Aranda E; Díaz-Rubio E
    Oncologist; 2012; 17(7):947-55. PubMed ID: 22643538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.
    Sastre J; Vidaurreta M; Gómez A; Rivera F; Massutí B; López MR; Abad A; Gallen M; Benavides M; Aranda E; Rubio ED;
    Clin Colorectal Cancer; 2013 Dec; 12(4):280-6. PubMed ID: 24012456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study.
    Bork U; Rahbari NN; Schölch S; Reissfelder C; Kahlert C; Büchler MW; Weitz J; Koch M
    Br J Cancer; 2015 Apr; 112(8):1306-13. PubMed ID: 25867263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Impact of Circulating Tumor Cell Detected Using a Novel Fluidic Cell Microarray Chip System in Patients with Breast Cancer.
    Sawada T; Araki J; Yamashita T; Masubuchi M; Chiyoda T; Yunokawa M; Hoshi K; Tao S; Yamamura S; Yatsushiro S; Abe K; Kataoka M; Shimoyama T; Maeda Y; Kuroi K; Tamura K; Sawazumi T; Minami H; Suda Y; Koizumi F
    EBioMedicine; 2016 Sep; 11():173-182. PubMed ID: 27495793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of peripheral circulating tumor cell counts in colorectal polyps and non-metastatic colorectal cancer.
    Yang C; Zhuang W; Hu Y; Zhu L
    World J Surg Oncol; 2018 Jan; 16(1):13. PubMed ID: 29357895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors.
    Goodman OB; Fink LM; Symanowski JT; Wong B; Grobaski B; Pomerantz D; Ma Y; Ward DC; Vogelzang NJ
    Cancer Epidemiol Biomarkers Prev; 2009 Jun; 18(6):1904-13. PubMed ID: 19505924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer.
    Banys-Paluchowski M; Fehm T; Janni W; Aktas B; Fasching PA; Kasimir-Bauer S; Milde-Langosch K; Pantel K; Rack B; Riethdorf S; Solomayer EF; Witzel I; Müller V
    BMC Cancer; 2018 May; 18(1):541. PubMed ID: 29739347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(®) CTC test.
    Adams DL; Stefansson S; Haudenschild C; Martin SS; Charpentier M; Chumsri S; Cristofanilli M; Tang CM; Alpaugh RK
    Cytometry A; 2015 Feb; 87(2):137-44. PubMed ID: 25515318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
    Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W;
    BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor cells in metastatic colorectal cancer: do we need an alternative cutoff?
    Gazzaniga P; Raimondi C; Gradilone A; Biondi Zoccai G; Nicolazzo C; Gandini O; Longo F; Tomao S; Lo Russo G; Seminara P; Vincenzi B; Chimenti I; Cristofanilli M; Frati L; Cortesi E
    J Cancer Res Clin Oncol; 2013 Aug; 139(8):1411-6. PubMed ID: 23736274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A New Size-based Platform for Circulating Tumor Cell Detection in Colorectal Cancer Patients.
    Oh BY; Kim J; Lee WY; Kim HC
    Clin Colorectal Cancer; 2017 Sep; 16(3):214-219. PubMed ID: 28209483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.